Alzheimer's disease is a progressive brain disorder, in which the brain gradually degenerates resulting in loss of memory, brain dysfunction, and cellular loss. It most often occurs in people aged above 65–70 years. A person afflicted with Alzheimer's also has to encounter issues with reasoning or judgment, steady decline in the ability to perform routine tasks, difficulty in learning, disorientation and loss of language skills. All these changes have a deep impact on not only the patient who is afflicted by the disease but also the care givers of the patient. This ultimately results in loss of independence of the patients and eventually complete dependence on the care givers. There are no definite symptoms for this disease and the biological changes in the brain at times can occur even decades before the first symptoms appear, making early diagnosis very difficult. By the time the patient reaches the late stages of the disease, they people are often unable to even communicate and become entirely dependent on their care givers even for simple day-to-day tasks. The current lot of Alzheimer's medications cannot cure or stop the disease from progressing. However they delay the progression or they might aid in lessening the intensity of the symptoms.
Market Industry Reports (MIR) has published a new report titled "Global Alzheimers Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global Alzheimers Drugs market was estimated to be over US $ 3.5 Bn in 2018. It is anticipated to grow at a CAGR of 7.2% from 2019 to 2030.
Major Key Players of the Alzheimer's Drugs Market are:
AC Immune, F. Hoffmann-La Roche, DAIICHI SANKYO COMPANY, Eli Lilly and Company, H. Lundbeck A/S, Eisai Co., Avanir Pharmaceuticals, Inc., Novartis AG, Janssen Global Services, LLC, AbbVie Inc. among others.
Read More @ http://www.sbwire.com/press-releases/alzheimers-drugs-market-to-witness-growth-acceleration-during-2019-2030-ac-immune-f-hoffmann-la-roche-daiichi-sankyo-1279034.htm
Growing prevalence rates of Alzheimers disease globally and rising geriatric population worldwide is anticipated to fuel the growth of Alzheimers drugs market. With the globally increasing ageing population, the number of patients suffering from Alzheimers disease is projected to grow during the forecast period. According to the World Health Organization (WHO) between the years 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. It is estimated that dementia affects 46.8 million people worldwide with an estimated cost of USD 818 billion. Alzheimers disease is the most common cause of dementia, with 9.9 million people newly diagnosed with dementia each year. Unfortunately there is no cure for Alzheimers, which has become one of the greatest public health challenges globally. These factors are expected fuel the Alzheimers Drugs Market in the forecast period. Current treatments focus on delaying the onset of the disease and on alleviating the symptoms, however they are unable to stop the disease from progressing as they do not alter or affect the underlying causes.
Read More @ http://www.sbwire.com/press-releases/alzheimers-drugs-market-to-witness-growth-acceleration-during-2019-2030-ac-immune-f-hoffmann-la-roche-daiichi-sankyo-1279034.htm
Market Industry Reports (MIR) has published a new report titled "Global Alzheimers Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global Alzheimers Drugs market was estimated to be over US $ 3.5 Bn in 2018. It is anticipated to grow at a CAGR of 7.2% from 2019 to 2030.
Major Key Players of the Alzheimer's Drugs Market are:
AC Immune, F. Hoffmann-La Roche, DAIICHI SANKYO COMPANY, Eli Lilly and Company, H. Lundbeck A/S, Eisai Co., Avanir Pharmaceuticals, Inc., Novartis AG, Janssen Global Services, LLC, AbbVie Inc. among others.
Read More @ http://www.sbwire.com/press-releases/alzheimers-drugs-market-to-witness-growth-acceleration-during-2019-2030-ac-immune-f-hoffmann-la-roche-daiichi-sankyo-1279034.htm
Growing prevalence rates of Alzheimers disease globally and rising geriatric population worldwide is anticipated to fuel the growth of Alzheimers drugs market. With the globally increasing ageing population, the number of patients suffering from Alzheimers disease is projected to grow during the forecast period. According to the World Health Organization (WHO) between the years 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. It is estimated that dementia affects 46.8 million people worldwide with an estimated cost of USD 818 billion. Alzheimers disease is the most common cause of dementia, with 9.9 million people newly diagnosed with dementia each year. Unfortunately there is no cure for Alzheimers, which has become one of the greatest public health challenges globally. These factors are expected fuel the Alzheimers Drugs Market in the forecast period. Current treatments focus on delaying the onset of the disease and on alleviating the symptoms, however they are unable to stop the disease from progressing as they do not alter or affect the underlying causes.
Read More @ http://www.sbwire.com/press-releases/alzheimers-drugs-market-to-witness-growth-acceleration-during-2019-2030-ac-immune-f-hoffmann-la-roche-daiichi-sankyo-1279034.htm
No comments:
Post a Comment